NCT07698756Not yet recruitingPhase 1
A Clinical Study of HRS-8797 in Healthy Participants
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect Following Single and Multiple Oral Doses of HRS-8797 Tablets in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- Jul 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07698756
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 74
- From Jul 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial.
- Blood donation/severe blood loss (≥400 mL) within 3 months, blood transfusion within 4 weeks before screening; planned blood donation during the trial.
- History of drug abuse/dependence; positive urine drug test at screening. Participation in other clinical trials within 3 months before screening or planned
- participation during the trial; within 5 half-lives of a prior drug (whichever is longer).
- Smoking history (≥5 cigarettes/day) within 4 weeks before screening; inability to abstain from tobacco during the trial;
Other illness
- A history or current severe diseases of multiple systems, or other diseases interfering with trial results.
- Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening.
Other
- Special dietary requirements and inability to comply with the unified diet.
- Difficulty in swallowing/venous blood collection; intolerance to intensive blood sampling.
- Other circumstances deemed unsuitable for trial participation by Researcher.
Who the study is looking for
- Healthy men and women aged 18 to 55 years old at informed consent signing
- Male body weight ≥50 kg , female ≥45 kg; BMI 18 to 28 kg/m² at screening and baseline
- Have no clinically significant abnormalities at screening and baseline
- Fertile females and males with fertile female partners: effective contraception consent, and sustained until 4 weeks after the last dose (abstinence or highly effective contraception); no sperm/egg donation
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.